Integrated Filing (Finance) Ind AS


Anglo-French Drugs & Industries Limited

General Information
Scrip code*000000
NSE Symbol*NOTLISTED
MSEI Symbol*AFDIL
ISIN*INE570E01016
Type of companyMain Board
Class of securityEquity
Date of start of financial year01-04-2025
Date of end of financial year31-03-2026
Date of board meeting when results were approved11-08-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange30-07-2025
Description of presentation currencyINR
Level of roundingLakhs
Reporting TypeQuarterly
Reporting QuarterFirst quarter
Nature of report standalone or consolidatedStandalone
Whether results are audited or unaudited for the quarter endedUnaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended
Segment ReportingMulti segment
Description of single segment
Start date of board meeting11-08-2025
Start time of board meeting14:15:00
End date of board meeting11-08-2025
End time of board meeting15:30:00
Whether cash flow statement is applicable on company
Type of cash flow statement
Declaration of unmodified opinion or statement on impact of audit qualificationNot applicable
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?false
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?falseTextual Information(1)

Amount in (Lakhs)

Financial Results - Ind-AS
Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-04-202501-04-2025
Date of end of reporting period30-06-202530-06-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Part IBlue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1Income
Revenue from operations2,723.002,723.00
Other income3,648.003,648.00
Total income6,371.006,371.00
2Expenses
(a)Cost of materials consumed636.00636.00
(b)Purchases of stock-in-trade952.00952.00
(c)Changes in inventories of finished goods, work-in-progress and stock-in-trade328.00328.00
(d)Employee benefit expense401.00401.00
(e)Finance costs48.0048.00
(f)Depreciation, depletion and amortisation expense79.0079.00
(g)Other Expenses
1Clearing Forwarding & Frieght Expenses18.6618.66
2Rebate & Discount Expenses39.3939.39
3Factory Power &Fuel Expenses41.3141.31
4Legal & Professional Fee49.2649.26
5Office & General Expenses26.2826.28
6Rent23.9523.95
7Repairs & Maintenance26.6626.66
8Tour & Travelling Expenses60.3360.33
9Vehicle Running & Maintenance50.1650.16
10Other Expenses99.0099.00
Total other expenses435.00435.00
Total expenses2,879.002,879.00
Total profit before exceptional items and tax3,492.003,492.00
4Exceptional items0.000.00
5Total profit before tax3,492.003,492.00
6Tax expense
7Current tax0.000.00
8Deferred tax0.000.00
9Total tax expenses0.000.00
10Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement0.000.00
11Net Profit Loss for the period from continuing operations3,492.003,492.00
12Profit (loss) from discontinued operations before tax0.000.00
13Tax expense of discontinued operations0.000.00
14Net profit (loss) from discontinued operation after tax0.000.00
15Share of profit (loss) of associates and joint ventures accounted for using equity method0.000.00
16Total profit (loss) for period3,492.003,492.00
17Other comprehensive income net of taxes3.003.00
18Total Comprehensive Income for the period3,495.003,495.00
19Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21Details of equity share capital
Paid-up equity share capital113.00113.00
Face value of equity share capital1010.00
22Reserves excluding revaluation reserve
23Earnings per share
iEarnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations309309.00
Diluted earnings (loss) per share from continuing operations309309.00
iiEarnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations00.00
Diluted earnings (loss) per share from discontinued operations00.00
iiiEarnings per equity share (for continuing and discontinued operations)
Basic earnings (loss) per share from continuing and discontinued operations309309.00
Diluted earnings (loss) per share from continuing and discontinued operations309309.00
24Debt equity ratio
25Debt service coverage ratio
26Interest service coverage ratio
27Remarks for debt equity ratio
28Remarks for debt service coverage ratio
29Remarks for interest service coverage ratio
30Disclosure of notes on financial results

Amount in (Lakhs)

Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results
Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-04-202501-04-2025
Date of end of reporting period30-06-202530-06-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
1Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
1Pharmaceuticals2,723.002,723.00
2Investments3,647.003,647.00
Total Segment Revenue6,370.006,370.00
Less: Inter segment revenue0.000.00
Revenue from operations6,370.006,370.00
2Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
1Pharmaceuticals41.0041.00
2Investments3,453.003,453.00
Total Profit before tax3,494.003,494.00
i. Finance cost1.00(1.00)
ii. Other Unallocable Expenditure net off Unallocable income0.000.00
Profit before tax3,495.003,495.00
3(Segment Asset - Segment Liabilities)
Segment Asset
1Pharmaceuticals14,035.0014,035.00
2Investments14,354.0014,354.00
Total Segment Assets28,389.0028,389.00
Un-allocable Assets0.000.00
Net Segment Assets28,389.0028,389.00
4Segment Liabilities
Segment Liabilities
1Pharmaceuticals12,383.0012,383.00
2Investments34.0034.00
Total Segment Liabilities12,417.0012,417.00
Un-allocable Liabilities0.000.00
Net Segment Liabilities12,417.0012,417.00
Disclosure of notes on segments

Amount in (Lakhs)

Other Comprehensive Income
Particulars3 months/ 6 months ended (dd-mm-yyyy)Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period01-04-202501-04-2025
Date of end of reporting period30-06-202530-06-2025
Whether results are audited or unauditedUnauditedUnaudited
Nature of report standalone or consolidatedStandaloneStandalone
Other comprehensive income [Abstract]
1Amount of items that will not be reclassified to profit and loss
1Amount of items that will not be reclassified to profit and loss3.003.00
Total Amount of items that will not be reclassified to profit and loss3.003.00
2Income tax relating to items that will not be reclassified to profit or loss0.000.00
3Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4Income tax relating to items that will be reclassified to profit or loss0.000.00
5Total Other comprehensive income